Standout Papers

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patient... 2022 2026 2023 2024248
  1. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
    Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 59 standout
Sub-graph 1 of 21

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
3 intermediate papers

Works of Tu Van Dao being referenced

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
2022 Standout
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
2022
and 1 more

Author Peers

Author Last Decade Papers Cites
Tu Van Dao 230 130 91 197 30 485
Wenjie Hu 176 83 182 183 31 480
Shengping Li 275 124 236 99 27 553
Yi‐Te Lee 148 76 66 242 25 488
Alireza Mohseni 91 85 64 145 36 453
Fatiha Merabtene 185 86 180 76 19 493
Jiacheng Xiao 175 58 100 109 26 526
Wei Zhang 132 75 98 163 39 524
Sirui Fu 93 73 72 219 26 506
Juan A. Santamaria‐Barria 279 105 89 94 32 545
Alessio Fabozzi 259 104 63 51 31 494

All Works

Loading papers...

Rankless by CCL
2026